Table 1.
Comparisons of Patients’ Clinical Characteristics
| Variables (N [%]) | Total (N=549) | IBR (N=93) | CBR (N=456) | P |
|---|---|---|---|---|
| Male Sex | 469 (85.4) | 76 (81.7) | 393 (86.2) | 0.262 |
| Age > 60 years old | 83 (15.1) | 9 (9.7) | 74 (16.2) | 0.115 |
| Diabetes mellitus | 19 (3.5) | 3 (3.2) | 16 (3.5) | 0.892 |
| Overweight* | 206 (37.5) | 34 (36.6) | 172 (37.7) | 0.907 |
| ASA score > 2 | 58 (10.6) | 9 (9.7) | 49 (10.7) | 0.855 |
| HBsAg (+) | 511 (93.1) | 85 (91.4) | 426 (93.4) | 0.501 |
| Anti-HCV (+) | 8 (1.5) | 2 (2.2) | 6 (1.3) | 0.629 |
| Cirrhosis | 431 (78.5) | 71 (76.3) | 360 (78.9) | 0.581 |
| Portal hypertension | 127 (23.1) | 19 (20.4) | 108 (23.7) | 0.590 |
| Child-Pugh grade B | 55 (10.0) | 12 (12.9) | 43 (9.4) | 0.342 |
| Preoperative AFP level | ||||
| Intermediately-high (401~1200 ng/mL) | 156 (28.4) | 16 (17.2) | 140 (30.7) | 0.008 |
| Extremely-high (> 1200 ng/mL) | 393 (71.6) | 77 (82.8) | 316 (69.3) | |
| Preoperative tumor rupture | 21 (3.8) | 12 (12.9) | 9 (2.0) | < 0.001 |
| Maximum tumor size > 5.0 cm | 290 (52.8) | 68 (73.1) | 222 (48.7) | < 0.001 |
| Multiple tumors | 87 (15.8) | 16 (17.2) | 71 (15.6) | 0.755 |
| Macrovascular invasion | 47 (8.6) | 18 (19.4) | 29 (6.4) | < 0.001 |
| Microvascular invasion | 252 (45.9) | 53 (57.0) | 199 (43.6) | 0.022 |
| Satellite nodules | 118 (21.5) | 28 (30.1) | 90 (19.7) | 0.037 |
| Incomplete tumor encapsulation | 289 (52.6) | 60 (64.5) | 229 (50.2) | 0.012 |
| Poor tumor differentiation | 370 (67.4) | 60 (64.5) | 310 (68.0) | 0.545 |
| Intraoperative blood loss > 600 mL | 111 (20.2) | 26 (28.0) | 85 (18.6) | 0.048 |
| Intraoperative blood transfusion | 111 (20.2) | 28 (30.1) | 83 (18.2) | 0.015 |
| Major hepatectomy | 128 (23.3) | 33 (35.5) | 95 (20.8) | 0.004 |
| Anatomical resection | 406 (74.0) | 58 (62.4) | 348 (76.3) | 0.007 |
| Resection margin < 1.0 cm | 269 (49.0) | 66 (71.0) | 203 (44.5) | < 0.001 |
Note: *Body mass index >24.0 kg/m2.
Abbreviations: ASA, American Society of Anesthesiologists; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; IBR, incomplete biomarker response; CBR, complete biomarker response.